Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Vamsidhar Velcheti

Hematology Oncology | Oncology | Hematology
New York University
550 1st Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Primitive Neuroectodermal Tumor (PNET)
New York University
550 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vamsidhar Velcheti is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Velcheti is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Mayo Clinic
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
550 1st Ave, New York, NY 10016
Other Locations
NEW YORK UNIVERSITY
160 E 34th St, New York, NY 10016
NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006
MAYO CLINIC JACKSONVILLE
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Topotecan Hydrochloride
Study Phase: Phase 2
Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Study of Aurora Kinase A Inhibitor VIC-1911 Monotherapy and in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
A Phase 1a/1b Study of Aurora Kinase A Inhibitor VIC-1911 Monotherapy and in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 01, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 1
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Decitabine, Tetrahydrouridine
Study Phase: Phase 2
A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 12, 2023
Intervention Type: Biological, Drug
Study Drugs: DRP-104, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Biological
Study Drugs: ALT-803, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
View 17 Less Clinical Trials

159 Total Publications

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
Journal: Immunotherapy
Published: October 17, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
 (3.4 miles away)
212-241-4572
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lyndon Kim is a Neurosurgery specialist and an Oncologist in New York, New York. Dr. Kim is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Jeffrey G. Schneider
Hematology Oncology | Hematology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Jeffrey G. Schneider
Hematology Oncology | Hematology | Oncology

New York University

297 Mineola Blvd, 
Mineola, NY 
 (17.3 miles away)
516-294-1377
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Schneider is a Hematologist Oncology specialist and a Hematologist in Mineola, New York. Dr. Schneider is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Gastrostomy.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Mark G. Kris
Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Mark G. Kris
Oncology

Memorial Solid Tumor Group

353 E 68th St, 
New York, NY 
 (1.8 miles away)
646-422-4300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Kris is an Oncologist in New York, New York. Dr. Kris is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Velcheti's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile